Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas E Witzig

Showing results (151-160 of 387) with videos related to

Pageof 39
Sort By:
Haematologica|June 19, 2025
Treatment approaches and clinical outcomes in primary colorectal MALT lymphoma: a single institution retrospective study of 66 patientsSuheil Albert Atallah-Yunes, Matthew J Rees, Thomas M Habermann, et al.
The Lancet. Oncology|March 29, 2011
Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 studyStephen M Ansell, Hui Tang, Paul J Kurtin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's LymphomaThomas E Witzig, Peter H Wiernik, Timothy Moore, et al.
American Journal of Hematology|July 13, 2017
Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphomaThomas E Witzig, Pier Luigi Zinzani, Thomas M Habermann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2002
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myelomaS Vincent Rajkumar, Suzanne Hayman, Morie A Gertz, et al.
Blood|June 18, 2005
Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myelomaGrzegorz S Nowakowski, Thomas E Witzig, David Dingli, et al.
Clinical and Translational Science|August 11, 2021
Prospective evaluation of high-dose methotrexate pharmacokinetics in adult patients with lymphoma using novel determinants of kidney functionJason N Barreto, Joel M Reid, Carrie A Thompson, et al.
Blood|October 24, 2002
Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosisAnimesh Pardanani, Thomas E Witzig, Georgene Schroeder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 29, 2004
Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapyThomas E Witzig, Peter T Silberstein, Charles L Loprinzi, et al.
Leukemia & Lymphoma|July 7, 2007
Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasoneLijo Simpson, Stephen M Ansell, Joseph P Colgan, et al.
Pageof 39

Showing results (151-160 of 387) with videos related to

Sort By:
Pageof 39
Haematologica|June 19, 2025
Treatment approaches and clinical outcomes in primary colorectal MALT lymphoma: a single institution retrospective study of 66 patientsSuheil Albert Atallah-Yunes, Matthew J Rees, Thomas M Habermann, et al.
The Lancet. Oncology|March 29, 2011
Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 studyStephen M Ansell, Hui Tang, Paul J Kurtin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's LymphomaThomas E Witzig, Peter H Wiernik, Timothy Moore, et al.
American Journal of Hematology|July 13, 2017
Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphomaThomas E Witzig, Pier Luigi Zinzani, Thomas M Habermann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2002
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myelomaS Vincent Rajkumar, Suzanne Hayman, Morie A Gertz, et al.
Blood|June 18, 2005
Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myelomaGrzegorz S Nowakowski, Thomas E Witzig, David Dingli, et al.
Clinical and Translational Science|August 11, 2021
Prospective evaluation of high-dose methotrexate pharmacokinetics in adult patients with lymphoma using novel determinants of kidney functionJason N Barreto, Joel M Reid, Carrie A Thompson, et al.
Blood|October 24, 2002
Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosisAnimesh Pardanani, Thomas E Witzig, Georgene Schroeder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 29, 2004
Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapyThomas E Witzig, Peter T Silberstein, Charles L Loprinzi, et al.
Leukemia & Lymphoma|July 7, 2007
Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasoneLijo Simpson, Stephen M Ansell, Joseph P Colgan, et al.
Pageof 39